Immatics Biotechnologies, a biotech firm with sites in Tübingen, Munich and Houston, has completed its Series E round of financing, raising a total of USD 58 million. The existing life science investors, which include dievini Hopp BioTech holding and Wellington Partners, have now been joined by Amgen, a world-leading biotechnology company and strategic partner of Immatics.

A team headed by lead partner Stefan-Ulrich Müller advised Immatics on all legal aspects of preparing, negotiating and implementing the transaction. Immatics has repeatedly drawn on the expertise of CMS lawyers, who have advised the company on all its rounds of financing since 2009.

Immatics will use the funding to continue its clinical research and development in the area of cancer immunotherapy.

CMS Germany

Stefan-Ulrich Müller, Lead Partner
Dr. Tilman Weichert, Counsel
Marcel Nurk, Senior Associate
Anton Hieber, Associate, alle Corporate/Venture Capital
Dr. Benedikt Forschner, Associate, Arbeitsrecht